HK Stocks Movement | Same Source Kang Medicine-B (02410) surged nearly 20% in the afternoon to hit a new high. Core product TY-959 has been approved for IND.

Tongyuan Kang Medicine-B (02410) rose nearly 20% in the afternoon, reaching a high of 38.5 Hong Kong dollars, hitting a new high since its listing, more than doubled compared to the IPO price of 12.1 Hong Kong dollars. As of the time of publication, it is up 11.52%, at 34.85 Hong Kong dollars, with a turnover of 11.8925 million Hong Kong dollars.

Zhitong FinanceNov 26 14:57

Third quarter IPO report: Hong Kong stock market once again witnessed billion-dollar projects, the number and amount of Chinese enterprise IPOs rebounded year-on-year

In Q3 2024, a total of 52 Chinese companies successfully IPO'd on A-shares, Hong Kong stocks, and US stocks. The number of IPOs decreased by 52.29% year-on-year, but increased by 18.18% compared to the previous period. In the first three quarters, the number of IPOs of Chinese companies globally decreased by 54.98% year-on-year.

36Kr NewsOct 21 10:30

TYK MEDICINES-B: Interim Report 2024

HKEXSep 27 16:45 · Announcements

Tongyuan Kang Pharmaceutical-B (02410.HK) applies for full circulation of H shares.

Kang Pharmaceuticals-B (02410.HK) announced that on September 13, 2024, the company has submitted an application to the China Securities Regulatory Commission for the conversion of 0.174 billion non-listed shares into H shares and the listing of these shares on the Hong Kong Stock Exchange. After obtaining record-filing and/or approval from all relevant regulatory institutions (including but not limited to the China Securities Regulatory Commission and the Hong Kong Stock Exchange), and complying with all applicable laws, regulations, and rules, these non-listed shares will be converted into H shares and be eligible for trading on the main board of the Hong Kong Stock Exchange.

Gelonghui FinanceSep 13 19:19

TYK Medicines Logs Wider Attributable Loss in H1

MT NewswiresAug 30 20:54

Tongyuan Kang Pharmaceutical-B (02410.HK) mid-term R&D costs increased by 0.138 billion yuan, a year-on-year increase of 15.3%.

According to the announcement of Tongyuan Kang Medicine-B (02410.HK) on August 30th, during the six months ended on June 30, 2024 and 2023, the group did not generate any revenue. During this period, research and development costs were RMB 137,758,000, a year-on-year increase of 15.3%. The increase was mainly attributed to the increase in experimental and testing expenses, especially the increase in experimental and testing expenses related to the development of core products. The loss for the reporting period increased by 26.3% from RMB 173,849,000 for the six months ended on June 30, 2023 to RMB 0 for the six months ended on June 30, 2024.

Gelonghui FinanceAug 30 17:26